Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Bitget Launches Global Graduate Program to Cultivate the Next Generation of Web3 Talent 17-02-2025, 15:35

Vectara Unveils Open-Source Hallucination Evaluation Model To Detect and Quantify Hallucinations in Top Large Language Models 6-11-2023, 17:00